HCPLive Network

MR-US Fusion Targeted Biopsy Ups Detection of Prostate Cancer

 
THURSDAY, Dec. 13 (HealthDay News) -- Targeted biopsy of suspected prostate cancer lesions, identified using magnetic resonance-ultrasound (MR-US) fusion, increases prostate cancer detection and detects aggressive tumors that may be missed by conventional biopsy, according to a study published in the January issue of The Journal of Urology.

Geoffrey A. Sonn, M.D., from the University of California Los Angeles, and colleagues used MR-US fusion prostate biopsy in 171 men (median age, 65 years) undergoing biopsy as part of active surveillance (106 men) or due to increased prostate-specific antigen levels with a prior negative conventional biopsy (65 men). MR-US fusion prostate biopsy locates lesions by magnetic resonance imaging (MRI) and fuses it with real-time ultrasound to generate a three-dimensional prostate model to allow targeted sampling. The men also had conventional systematic biopsies taken.

The researchers identified prostate cancer in 53 percent of men, of whom 38 percent had cancer with Gleason grade 7 or greater. Of these highly-aggressive cancers, 38 percent were detected only by targeted biopsy. Of the 16 men with the highest level of suspicion by MRI (image grade 5 target), 94 percent had prostate cancer.

"Prostate lesions identified on MRI can be accurately targeted with MR-US fusion biopsy in a clinic setting using local anesthesia," Sonn and colleagues conclude. "Targeted prostate biopsy has the potential to improve the diagnosis of prostate cancer and may aid in the selection of patients for active surveillance and focal therapy."
 

Abstract
Full Text (subscription or payment may be required)

 
Copyright © 2012 HealthDay. All rights reserved.
 
 

Further Reading
Magnetic resonance is an effective alternative to biopsy for identifying and quantifying fats in the liver, according to results from a study led by a research team at the University of the Basque Country.
For patients with breast cancer with spinal metastases, estrogen receptor/hormone receptor-negative status is associated with worse survival, according to a study published in the Sept. 1 issue of Spine.
Less than half of all Americans got a flu shot last year, so U.S. health officials on Thursday urged that everyone 6 months and older get vaccinated for the coming flu season. "It's really unfortunate that half of Americans are not getting the protection from flu they could get," said Thomas Frieden, MD, director of the U.S. Centers for Disease Control and Prevention, during a morning news conference.
The investigational drug alpelisib (previously known as BYL719) appears to inhibit activation of the pathway that leads to resistance to cetuximab, an anti-epidermal growth factor receptor agent used in the treatment of head and neck cancer. These findings were presented at the American Association for Cancer Research's special conference "Targeting the PI3K-mTOR Network in Cancer," held from Sept. 14 to 17 in Philadelphia.
Strategies are presented to help physicians lower their tax burden in an article published Sept. 2 in Medical Economics.
There is little evidence that testosterone replacement therapy effectively treats normally declining levels of the hormone in aging American males, a US Food and Drug Administration advisory panel said Wednesday.
The five-point Deauville scale, used to score 18F-fluorodeoxyglucose (FDG) uptake on FDG positron emission tomography-computed tomography scans, has prognostic value in follicular lymphoma, according to a study published online Sept. 18 in The Lancet Haematology.
More Reading